Alpha Tau Medical (NASDAQ:DRTSW – Get Free Report) is expected to announce its resultson Monday, May 25th. Analysts expect the company to announce earnings of ($0.1236) per share and revenue of $0.05 million for the quarter.
Alpha Tau Medical Stock Performance
DRTSW stock opened at $2.15 on Monday. The company’s 50 day moving average price is $1.06 and its 200 day moving average price is $0.78. Alpha Tau Medical has a fifty-two week low of $0.20 and a fifty-two week high of $2.30.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd. is a clinical-stage medical technology company focused on the development of alpha-emitting radiation therapy for the treatment of solid tumor cancers. The company’s proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) platform leverages the short-range, high-energy alpha particles emitted by radium-224 to penetrate tumor tissues more effectively than conventional external-beam radiation. By implanting thin, needle-like sources directly into a tumor, Alpha DaRT delivers concentrated doses of radiation to malignant cells while sparing surrounding healthy tissue.
The Alpha DaRT technology is designed to enhance local tumor control in a variety of solid tumors, including head and neck, breast, skin, and pancreatic cancers.
Read More
- Five stocks we like better than Alpha Tau Medical
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
